PNC-27 10mg

PNC-27 is a synthetically created peptide designed to specifically target and destroy cancer cells. It is a member of the PNC set of investigational proteins designed to attach to malformed (cancerous) cells and cause them to die through cell necrosis, all while leaving normal, healthy cells intact and unharmed.

The PNC-27 peptide contains an HDM-2 binding domain corresponding to residues 12-26 of p53 and a transmembrane-penetrating domain. This has been found to enable the peptide to bind to and kill cancer cells through membranolysis, or disruption of the cell membrane.

Through research and study on animal subjects, the PNC-27 peptide has been shown to be highly effective in selectively targeting a wide variety of specific forms of cancer, including pancreatic cancer, breast cancer, leukemia, melanoma, and additional cancer lines.

How Does the PNC-27 Peptide Work?

PNC proteins were first theorized and created in 2000 by Drs. Matthew Pincus and Joseph Michl at the SUNY Downstate Medical Center in New York. Although they were originally intended to combat HIV, PNC-27 showed a remarkable ability to bind to cancer cells, causing them to die, while leaving healthy cells undamaged.

The PNC-27 cancer peptide is a nontoxic compound that causes the death of cancer cells only, leaving all other healthy cells unaffected. It is able to do this by attaching to the membranes of the individual cancer cells, creating holes in those membranes. As a result of the holes, rapid implosion occurs, leading to swift cell death due to the osmotic pressure difference in the inside vs. outside of the tumor cells.

PNC-27 accomplishes this due to its affinity for binding to a protein called HDM-2. Cancer cells have HDM-2 in their cell membranes. When the PNC-27 peptide is administered, it immediately travels to the HDM-2 located in the membranes of cancerous cells. By binding to them, it creates pores or holes in the cell membrane, causing “membranolysis,” or death of the cell membrane. This in turn leads to the destruction of the cancer cell.

Clinical Studies of the PNC-27 Peptide

In a paper published by the American Association for Cancer Research in 2010, Drs. Ehsan Sarafraz-Yazdi et al. revealed in depth how the PNC-27 cancer peptide exerted its effects and what its novel mechanism of action meant for the field of cancer research. The paper’s authors reported that the peptide’s mechanism of action is due to the formation of oligomeric pores in the plasma membrane of tumor cells. Concurrently, oligomeric pores are not formed in untransformed, or non-tumor, cells. Further, they noted that it has been shown that MDM2 as a targeting molecule leads to PNC-27 selectivity towards cancer cells by its mis-localization to cancer cell plasma membranes.

Researchers concluded that these findings are descriptive of the unique localization of MDM2 variants in the plasma membranes of cancerous cells.[5] Further, they stated that this knowledge may hint at great promise for the PNC-27 peptide as a future anti-cancer drug pending clinical trials.

The PNC-27 research peptide has even been the subject of a fascinating Ted Talk. It can be seen conducted by Dr. Sarafraz-Yazdi, an Assistant Professor in the Division of Gynecologic Oncology at The State University of New York (SUNY).

Molecular formula: C188H293N53O44S
Molar Mass: 4031.7

10 mg of powdered PNC-27 peptide per 3cc vi

For research purposes only.